Back to Report Store Home

Hereditary Hematological Disorders Drug Development Pipeline Review, 2018

  • Published: Oct-2018
  • Report Code: GBIHC048IDB
  • Report Format: pdf

Description

List of Figures

Figure 1: Number of Products under Development for Thalassemia

Figure 2: Number of Products under Development by Companies, Thalassemia

Figure 3: Number of Products under Development by Universities/Institutes, Thalassemia

Figure 4: Number of Products under Development for Hemophilia B

Figure 5: Number of Products under Development by Companies, Hemophilia B

Figure 6: Number of Products under Development by Universities/Institutes, Hemophilia B

Figure 7: Number of Products under Development for Sickle Cell Disease

Figure 8: Number of Products under Development by Companies, Sickle Cell Disease

Figure 9: Number of Products under Development by Universities/Institutes, Sickle Cell Disease

Figure 10: Number of Products by Top 10 Targets, Thalassemia

Figure 11: Number of Products by Stage and Top 10 Targets, Thalassemia

Figure 12: Number of Products by Top 10 Mechanism of Actions, Thalassemia

Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions, Thalassemia

Figure 14: Number of Products by Routes of Administration, Thalassemia

Figure 15: Number of Products by Stage and Routes of Administration, Thalassemia

Figure 16: Number of Products by Molecule Types, Thalassemia

Figure 17: Number of Products by Stage and Molecule Types, Thalassemia

Figure 18: Number of Products by Targets, Hemophilia B

Figure 19: Number of Products by Stage and Targets, Hemophilia B

Figure 20: Number of Products by Mechanism of Actions, Hemophilia B

Figure 21: Number of Products by Stage and Mechanism of Actions, Hemophilia B

Figure 22: Number of Products by Routes of Administration, Hemophilia B

Figure 23: Number of Products by Stage and Routes of Administration, Hemophilia B

Figure 24: Number of Products by Molecule Types, Hemophilia B

Figure 25: Number of Products by Stage and Molecule Types, Hemophilia B

Figure 26: Number of Products by Top 10 Targets, Sickle Cell Disease

Figure 27: Number of Products by Stage and Top 10 Targets, Sickle Cell Disease

Figure 28: Number of Products by Top 10 Mechanism of Actions, Sickle Cell Disease

Figure 29: Number of Products by Stage and Top 10 Mechanism of Actions, Sickle Cell Disease

Figure 30: Number of Products by Routes of Administration, Sickle Cell Disease

Figure 31: Number of Products by Stage and Routes of Administration, Sickle Cell Disease

Figure 32: Number of Products by Top 10 Molecule Types, Sickle Cell Disease

Figure 33: Number of Products by Stage and Top 10 Molecule Types, Sickle Cell Disease

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$11985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards